Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Academy of Oncology Nurse & Patient Navigators
    The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

October 2018 Vol 4 No 5

Genetic Testing Can Help to Guide the Treatment of Patients with Chronic Lymphocytic Leukemia
Knowing if the patient’s chronic lymphocytic leukemia (CLL) has genetic abnormalities through genetic testing can help doctors select the best treatment. Read More ›

Tibsovo First Drug Approved by the FDA for AML with IDH1 Mutation
In July 2018, the FDA approved Tibsovo (ivo-sidenib; from Agios Pharmaceuticals), the first IDH1 inhibitor, for the treatment of adults with relapsed (returning) or refractory (not responding to treatment) acute myeloid leukemia (AML) and a susceptible IDH1 genetic mutation. Read More ›

FDA Approved Opdivo for Metastatic Small-Cell Lung Cancer

Lenvima a New Option Approved for Initial Treatment of Liver Cancer
Previously approved for thyroid cancer and kidney cancer, the FDA has recently approved Lenvima as the first treatment for patients with liver cancer. Read More ›

Braftovi plus Mektovi a New Combination for Metastatic Melanoma with BRAF Mutation

Opdivo plus Yervoy First Immunotherapy Regimen for Initial Treatment of Kidney Cancer
The use of Opdivo with Yervoy is the first immunotherapy combination therapy approved by the FDA for patients with kidney cancer. Read More ›

Do We Become Complacent Survivors After a Few Years of Cancer Remission?
Breast cancer survivor Ginger Modiri cautions those in remission to avoid becoming complacent and to keep up with their follow-up screenings. Read More ›

5 People You Didn’t Know You Need on Your Breast Cancer Team
Dr. Citrin explains the role of 5 experts who are essential for meeting the physical, emotional, and therapy needs of patients with breast cancer. Read More ›

There’s Room for All of It

The Body I Need
Sharon Chappell expresses her experience with breast cancer through typography, art, and poetry. Read More ›

Page 1 of 3